Sentences with phrase «of diabetes therapy»

By following the therapeutic regimen summarized above, it will be possible to reach a good control of blood glucose levels, which is the goal of diabetes therapy, with resulting resolution of diabetes clinical symptoms and prevention of chronic life - threatening complications.

The adverse consequences of diabetes therapy, including the annual incidence of severe hypoglycemia resulting in loss of consciousness or seizure, which is recognized to increase with intensive therapy, and of diabetic ketoacidosis are given in Table 4.

Criticism of the diabetes therapy Avandia is reaching a fever pitch.

Not exact matches

Pre-eclampsia, gestational diabetes, blood pressure... Not to mention forced cessation of any medically - necessary drugs or therapies that might hurt the precious little fetal blob.

About Blog iPAG Scotland is a group made up of pump users, potential pump users or parents of children with Type 1 Diabetes interested in Insulin Pump Therapy & New Technology.

My uncle has diabetes and might have prostate cancer, I found out today, but instead of changing his diet he will just take drugs and the conventional therapies and feels horrible.

Not till later did I find out from my OB that my years of diabetes, PCOS and hormone therapy that I received for my endometrial cancer caused hormone imbalances which led to my inability to produce milk.

Insulin pump therapy Insulin pump therapy should be offered as a treatment for diabetes to children, young persons and adults with Type 1 diabetes as part of a cohesive and comprehensive diabetes service..

Further studies into this relationship could lead to the development of therapies that treat disorders such as obesity and diabetes.

«We envision that our nanoparticle therapy could be used to speed the healing of all sorts of wounds, including everyday cuts and burns, surgical incisions, and chronic skin ulcers, which are a particular problem in the elderly and people with diabetes,» said study co-leader David J. Sharp, Ph.D., professor of physiology & biophysics at Einstein.

In addition, the development of therapies that could potentially halt patients» progression from pancreatic inflammation to diabetes has been hampered by the long lead times needed in order to tell whether a given therapy has an effect.

«Using Streptozotocin - induced type I diabetes and cornea epithelial wounding experimental models, we made novel observations that may soon lead to innovative therapies to treat DPN and ulcerations of the cornea and skin in diabetic patients,» said Yu.

This could give doctors an opportunity to reduce the use of insulin therapy, and might help to reduce the diabetes epidemic, says Dr. Pshezhetsky.

«In further studies we want to examine how different combination therapies affect the retinal proteins, in order to achieve a better understanding of the causes and treatment of this diabetes complication,» added Dr. Stefanie Hauck (PROT).

Lowering of LDL - C levels by statin therapy modestly increases the risk of type 2 diabetes, but it is unknown whether this effect is specific to statins.

Researchers at New York University College of Dentistry (NYU Dentistry) have described a new target that may open the door to developing therapies for preventing bone fractures in people with type 2 diabetes.

Type 2 diabetes afflicts more than 300 million people globally, and as many as 15 % of those patients can not take the first - line therapy metformin because of kidney damage risks.

Experiments with a compound called TNP [N2 -(m - Trifluorobenzyl), N6 -(p - nitrobenzyl) purine], which researchers often use to study obesity and diabetes, show that in mice the therapy can promote the formation of new bone.

Diabetes researchers are considering various replacements for insulin injections: Transplanting new pancreatic islet cells that make insulin, coaxing the patient's own islets to regenerate, or treating diabetics early in the disease with immune - suppressing therapies to prevent their body from destroying the rest of their pancreatic islets.

The study, «AKR1B1 promotes basal - like breast cancer progression by a positive feedback loop that activates the EMT program,» which has been published in The Journal of Experimental Medicine, suggests that an inhibitor of this enzyme currently used to treat diabetes patients could be an effective therapy for this frequently deadly form of cancer.

The new method of estimating blood sugar could also help researchers evaluate new therapies for diabetes in clinical trials, he noted.

She continued: «Therefore, in further studies, we should investigate how and at what point DPP4 inhibitors can be used in diabetes therapy to prevent the development of non-alcoholic fatty liver disease.»

Biopharmaceutical drugs, which are used in a wide range of therapies including vaccines and treatments for diabetes and cancer, are typically produced in large, centralized fermentation plants.

Antigen - specific therapy using insulin before the development of autoantibodies may induce protective immune responses that prevent the emergence of autoimmunity and subsequent type 1 diabetes in genetically at - risk children, according to background information in the article.

The promise of autoantigen - specific therapy for prevention of type 1 diabetes in humans has yet to be realized.

«While expanding beta cell mass may still be desirable for future diabetes therapy, improving the local environment of the otherwise healthy aged beta cell could prevent age - associated deterioration in glucose homeostasis and thereby promote healthy ageing, which is conceptually novel and highly exciting,» says Per - Olof Berggren.

Scientists have been investigating molecular pathways that govern beta cell growth in hopes of finding new therapies that would help people regain blood glucose control after the onset of diabetes.

The discovery provides an opportunity to pursue the development of novel drug therapies to address obesity, type 2 diabetes and related metabolic diseases.

«This would aid the development of the next generation of treatments as well as combination therapies for Type 2 diabetes.»

A growing body of evidence suggests that rapid detection of, and aggressive new therapies for, type - 1 diabetes benefit patients in the long run, possibly halting the autoimmune attack on the pancreas and preserving some of the body's ability to make insulin.

It demonstrates a completely novel mechanism of predisposition to diabetes that could lead to novel therapies,» says Adrian Vella, M.D., Mayo Clinic endocrinologist and senior author of the study.

«The addition of osteocalcin as a metabolic regulator may one day lead to novel therapies, but we need to understand much better how it works and how it fits into physiology before such therapies can be attempted in humans,» says endocrinologist Mitch Lazar, director of the Institute for Diabetes, Obesity, and Metabolism at the University of Pennsylvania.

A study published January 4th in Cell Stem Cell demonstrates that a gene therapy approach can lead to the long - term survival of functional beta cells as well as normal blood glucose levels for an extended period of time in mice with diabetes.

«With the new test, not only do we anticipate being able to diagnose diabetes more efficiently and more broadly, we will also understand diabetes better — both the natural history and how new therapies impact the body,» said Brian Feldman, MD, PhD, assistant professor of pediatric endocrinology and the Bechtel Endowed Faculty Scholar in Pediatric Translational Medicine.

«A clinical trial in both type 1 and type 2 diabetics in the immediate foreseeable future is quite realistic, given the impressive nature of the reversal of the diabetes, along with the feasibility in patients to do AAV gene therapy.»

Two teams of scientists suggest that activating immune cells in fat can convert the tissue from a type of fat that stores energy to one that burns it, opening up potential new therapies for obesity and diabetes.

The new findings could be used to inform precision - medicine approaches that help minimize a person's risk for common diseases — such as diabetes, cardiovascular disease and cancer — by tailoring diet - based prevention and therapy to the specific needs of an individual.

«This drop in A1C due to nutrition therapy alone is much better than what we have been able to achieve with many of the current medications for type 2 diabetes,» said Dr. Hamdy.

Verchere also believes IAPP is «a big player» in the progression of type 2 diabetes, and that therapies that prevent the clumps of proteins from forming are needed.

Raydiance's technology has attracted the attention of the U.S. Food and Drug Administration (FDA), which in July 2007 signed the company to a two - year cooperative research and development agreement that has allowed the FDA's Center for Devices and Radiological Health (CDRH) to evaluate the use, safety and effectiveness of Raydiance's USP laser system in a number of areas, including the ablation of corneal tissues in refractive surgery and corneal repair; the administration of light therapy for treating cancer, cardiovascular disease and diabetes; and the removal of plaque on teeth without damaging the enamel.

«Moving forward, this more sophisticated understanding of the relationship between diabetes and obesity should enable researchers not only to develop therapies targeting these mechanisms, but also to identify the appropriate patients to whom these therapies should be targeted.»

«Knowledge that aspirin is safe could have implications extending beyond the world of heart failure since ACE inhibitors are also used as a front - line therapy for hypertension and diabetes,» adds Graham.

According to Sinclair, all of the mammalian SIRT genes (and their proteins) are possible drug targets for therapies aimed at extending life, as well as staving off age - related illnesses, such as Alzheimer's disease, cancers and metabolic disorders, like diabetes.

With these findings, Helmholtz Zentrum München scientists have discovered key molecular functions of stem cell differentiation which could be used for beta cell replacement therapy in diabetes.

The technique «potentially provides ways to create model systems for studying the genetic basis of diabetes, or to discover novel therapies to enhance existing β cells,» Ferrer says.

Scientists from the Helmholtz Zentrum München have reported in the journal Diabetes Care that high - affinity GAD antibodies are found in patients who produce only a little of their own insulin and who will require insulin therapy after only a relatively short time.

«Given the growing epidemic of obesity, diabetes, and NAFLD, this study brings to the attention of policymakers, providers, pharmaceutical companies, payers, and patients the critical importance of understanding NAFLD and establishing a policy for prevention, early detection, and effective therapy,» said Dr. Younossi.

Solt notes that the study strongly suggests that Th17 cells have a pathological role in the development of type 1 diabetes and use of ROR - specific synthetic compounds targeting this cell type may have potential as a preventative therapy for type 1 diabetes.

A study led by Daniel White, assistant professor of physical therapy at the University of Delaware, found that an intensive regimen of regular exercise and a healthy diet might reduce the short - term onset of knee pain for overweight adults with Type 2 diabetes mellitus.

March 23, 2006 Efforts to replicate controversial diabetes therapy bring partial success An effort by researchers at the University of Chicago to confirm the results of a high - profile study that brought extraordinary hope to diabetes researchers and patients worldwide has met with considerable, but not complete, success.